Polar Capital Holdings Plc Has $40.07 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Polar Capital Holdings Plc reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,249 shares of the biopharmaceutical company's stock after selling 15,546 shares during the quarter. Polar Capital Holdings Plc owned about 0.05% of Regeneron Pharmaceuticals worth $40,068,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of REGN. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $802,036,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the period. Amundi lifted its holdings in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after purchasing an additional 393,997 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. The Goldman Sachs Group dropped their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $15.13 during trading on Tuesday, reaching $610.79. 431,043 shares of the company were exchanged, compared to its average volume of 788,095. The stock has a market cap of $65.94 billion, a P/E ratio of 15.95, a PEG ratio of 2.34 and a beta of 0.43. The firm has a 50 day moving average of $598.10 and a 200 day moving average of $680.17. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the previous year, the company earned $9.55 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.